Palatin Technologies, Inc. (PTN) |
1.885 -0.005 (-0.26%) 04-19 12:39 |
Open: | 1.89 |
High: | 1.95 |
Low: | 1.86 |
Volume: | 90,462 |
Market Cap: | 30(M) |
PE Ratio: | -0.63 |
Exchange: | American Stock Exchange |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 2.88 |
Resistance 1: | 2.34 |
Pivot price: | 1.86 |
Support 1: | 1.46 |
Support 2: | 1.21 |
52w High: | 5.65 |
52w Low: | 1.43 |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
EPS | -30530000.000 |
Book Value | 0.000 |
PEG Ratio | 0.00 |
Gross Profit | 156.264 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | -290.07 |
Return on Assets (ttm) | -99.1 |
Return on Equity (ttm) | -1.0 |
Thu, 11 Apr 2024
Palatin Technologies director buys $12.7k in stock By Investing.com - Investing.com
Mon, 08 Apr 2024
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American ... - PR Newswire
Wed, 06 Mar 2024
Palatin Technologies, Inc. (PTN) Stock Is Lower By -21.63% This Week: Buy, Hold, or Sell? - InvestorsObserver
Wed, 28 Feb 2024
Palatin stock plunges 40% on mixed Phase 3 data for dry eye drug (NYSE:PTN) - Seeking Alpha
Wed, 28 Feb 2024
Where Will Palatin Technologies, Inc. (PTN) Stock Go Next After It Has Fallen 18.79% in a Week? - InvestorsObserver
Fri, 16 Feb 2024
Palatin Technologies, Inc. (AMEX:PTN) Q2 2024 Earnings Call Transcript - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |